Top Markets
Coin of the day
Xuanzhubio-b Xuanzhubio-b

Xuanzhubio-b

2575
Kedudukan dalam Saham #11437
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Harga Saham
$1.35
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$700.36M
Perubahan (1 hari)
0.09%
Perubahan (1 tahun)
-
Negara
CN
Perdagangan Xuanzhubio-b (2575)

Kategori

Sejarah pecahan saham untuk Xuanzhubio-b (2575)
Saham Xuanzhubio-b (simbol: 2575) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Aug 30, 2026.
Satu saham 2575 yang dibeli sebelum Aug 30, 2026 kini bersamaan dengan 0 saham 2575.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa